SCHEMBL25832955

SCHEMBL25832955

O=C(COc1ccc(CC2SCNC2=O)cc1)c1ccccc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 8/20 0.49
MPC2 O95563 2/20 0.42
CYP2C8 P10632 2/20 0.42
CYP2C9 P11712 2/20 0.42
FFAR1 O14842 5/20 0.37
RARG P13631 1/20 0.36
RXRA P19793 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
PPARA Q07869 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25832961 0.84 PPARG (0.68) PPARGMPC2CYP2C8CYP2C9FFAR1
SCHEMBL936483 0.83 PPARG (0.72) PPARGMPC2CYP2C8CYP2C9FFAR1
SCHEMBL19217857 0.81 PPARG (0.49) PPARGMPC2CYP2C8CYP2C9FFAR1
SCHEMBL8282070 0.80 PPARG (0.47) PPARGMPC2CYP2C8CYP2C9FFAR1
SCHEMBL24050980 0.79 PPARG (0.47) PPARGMPC2CYP2C8CYP2C9FFAR1
SCHEMBL25833062 0.78 PPARG (0.54) PPARGMPC2CYP2C8CYP2C9NPC1
SCHEMBL24212244 0.77 PPARG (0.71) PPARGMPC2CYP2C8CYP2C9FFAR1
SCHEMBL8176942 0.74 HTT (0.51) PPARGFFAR1RXRAPPARAMEN1
SCHEMBL29207071 0.72 RAB9A (0.56) NPC1RAB9AMEN1ALDH1A1MAPT
SCHEMBL18541489 0.70 PPARG (0.73) PPARGMPC2CYP2C8CYP2C9FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210825-A1 METHODS AND COMPOSITIONS FOR TREATING SUBJECTS WITH METABOLIC DISORDERS AND CORONAVIRUS INFECTIONS CIRIUS THERAPEUTICS, INC. 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210825-A1 METHODS AND COMPOSITIONS FOR TREATING SUBJECTS WITH METABOLIC DISORDERS AND CORONAVIRUS INFECTIONS ACE, DPP4, ACE2 PPARG 19/4885MPC2 223/4885CYP2C8 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.